Immunova Therapeutics
Pre-clinicalCAR-T Cells CAR-T cells are engineered to express synthetic receptors composed of an antibody-derived single-chain variable fragment (scFv) fused to intracellular signaling domains. Unlike TCRs, CARs recognize intact antigens on the cell surface in an MHC-independent manner. CAR-T therapies have shown remarkable success in treating hematologic malignancies such as B cell leukemias and lymphomas by targeting CD19 or BCMA.
About
CAR-T Cells CAR-T cells are engineered to express synthetic receptors composed of an antibody-derived single-chain variable fragment (scFv) fused to intracellular signaling domains. Unlike TCRs, CARs recognize intact antigens on the cell surface in an MHC-independent manner. CAR-T therapies have shown remarkable success in treating hematologic malignancies such as B cell leukemias and lymphomas by targeting CD19 or BCMA.
Funding History
2Total raised: $25M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile